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The amyloid hypothesis suggests that the process of
amyloid- protein (A) fibrillogenesis is responsible for
triggering a cascade of physiological events that con-
tribute directly to the initiation and progression of Alz-
heimer’s disease. Consequently, preventing this process
might provide a viable therapeutic strategy for slowing
and/or preventing the progression of this devastating
disease. A promising strategy to achieve prevention of
this disease is to discover compounds that inhibit A
polymerization and deposition. Herein, we describe a
new class of small molecules that inhibit A aggrega-
tion, which is based on the chemical structure of apo-
morphine. These molecules were found to interfere with
A1–40 fibrillization as determined by transmission
electron microscopy, Thioflavin T fluorescence and ve-
locity sedimentation analytical ultracentrifugation
studies. Using electron microscopy, time-dependent
studies demonstrate that apomorphine and its deriva-
tives promote the oligomerization of A but inhibit its
fibrillization. Preliminary structural activity studies
demonstrate that the 10,11-dihydroxy substitutions of
the D-ring of apomorphine are required for the inhibi-
tory effectiveness of these aporphines, and methylation
of these hydroxyl groups reduces their inhibitory po-
tency. The ability of these small molecules to inhibit A
amyloid fibril formation appears to be linked to their
tendency to undergo rapid autoxidation, suggesting
that autoxidation product(s) acts directly or indirectly
on A and inhibits its fibrillization. The inhibitory prop-
erties of the compounds presented suggest a new class of
small molecules that could serve as a scaffold for the
design of more efficient inhibitors of A amyloidogen-
esis in vivo.
Alzheimer’s disease (AD)1 is a progressive neurodegenera-
tive disease that is characterized by the presence of extracel-
lular amyloid plaques and intraneuronal neurofibrillary tan-
gles in the brains of AD patients (1–3). Biochemical analysis of
amyloid plaques revealed that the main constituent of amyloid
plaques is fibrillar aggregates of a 39–42-residue peptide re-
ferred to as the amyloid- (A) protein (4). Several lines of
evidence point toward a central role for the process of A
amyloid fibril formation in the etiology of AD. Transgenic ani-
mals overexpressing mutant forms of the amyloid precursor
protein develop amyloid plaques, one of the major histopatho-
logic hallmarks of AD (5). Several pathogenic AD mutations
have been shown to effect the processing of amyloid precursor
protein, resulting in increased A levels, in particular the more
amyloidogenic A42 (6). These data implicate the process of
amyloid formation as the cause of neurodegeneration and dis-
ease progression in AD. Thus, a small molecule that reduces A
production or slows and/or inhibits A aggregation would be
considered a useful therapeutic strategy for slowing and/or
preventing the progression of AD (7–10).
Although a causal link between amyloid fibril formation and
AD is supported by genetic, neuropathologic, and biochemical
evidence, the mechanism by which A assemblies cause neu-
rodegeneration is controversial (11). Fibrillization of A occurs
via a complex multistep-nucleated polymerization mechanism
and proceeds via oligomeric intermediates called protofibrils.
The neurotoxicity of A is highly dependent on it’s conforma-
tion, quaternary structure, and the morphology of the aggre-
gates formed (12–15). Monomeric A is thought to be not neu-
rotoxic, whereas both protofibrillar and fibrillar species of A
exhibit neurotoxicity in cell-based assays (16–18). Although A
toxicity has been reported to be associated with A-mediated
oxidative stress (generation of free radicals and reactive oxygen
species independent of the aggregation state of A) (19, 20),
recent reports suggest that monomeric A1–40 and A1–42
acts as a natural antioxidant and protects neurons against
metal-induced oxidative damage, whereas aggregated A acts
as a free radical generator, implying an aggregation-dependent
biological function of A (21).
Several therapeutic strategies have been proposed for the
treatment of amyloid-related disorders caused by the misfold-
ing and aggregation of a precursor protein or a fragment
thereof (10, 22, 23). For example, the stabilization of the native
three-dimensional structure of the amyloidogenic protein
transthyretin (TTR) by its natural ligands (thyroxin, retinol-
binding protein) or analogues will inhibit TTR fibril formation
in vitro (24, 25). Fibril formation by TTR or TTR variants has
been linked to the etiology of systemic amyloidosis and familial
amyloid polyneuropathy (26). The fact that A is unstructured
and its natural partner(s) has not been found makes structural-
based design of compounds that stabilize the native nontoxic
conformation a challenging task. However, limited screening
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has resulted in several compounds that inhibit A fibrillogen-
esis and/or A-associated neurotoxicity in vitro including small
molecules, proteins, antibodies, and small synthetic peptides
(27–30).
In this paper, we report a new class of inhibitors of A
fibrillization based on the parent compound apomorphine. In
vitro studies indicate that these compounds strongly interfere
with the fibrillization of A1–40. Previously, the high suscep-
tibility of apomorphine to autoxidation was thought to limit its
efficacy (31–33). However, our results demonstrate that autox-
idation of apomorphine and its derivatives is critical for their
inhibitory activity, suggesting that one or several of the autox-
idation products of apomorphine interacts with monomeric and
protofibrillar forms of A in a manner that leads to inhibition
fibril formation. Electron microscopy and sedimentation veloc-
ity studies demonstrate that apomorphine and several of its
derivatives bind to A and promote its oligomerization, result-
ing in the accumulation of protofibrillar intermediates (34, 35).
These compounds can stabilize protofibrils for approximately 2
weeks at 4 or 25 °C, producing a novel method for investigating
the biophysical and toxic properties of protofibrils. More impor-
tantly, these compounds may provide useful tools for evaluat-
ing the role of A fibrillogenesis in the pathogenesis of AD.
EXPERIMENTAL PROCEDURES
Apomorphine (HBr), (R)-(-)norapomorphine hydrobromide (D040),
(R)-(-)2,10,11-trihydroxyaporphine hydrobromide (D029), (R)-(-)propyl-
norapomorphine hydrochloride (D027), (R)-(-)2,10,11-trihydroxy-N-
propyl-norapomorphine hydrobromide (D030), bulbocapnine hydro-
chloride, (R)-(-)10,11-methylenedioxy-N-n-propylnoraporphine hydro-
chloride, (R)-(-)apocodeine hydrochloride, isocrydine hydrochloride,
dopamine, and norepinephrine were purchased from Sigma or ICN.
Thioflavin T and Congo Red were purchased from Aldrich.
Preparation of A Protein for Fibrillization Studies—Purified
A1–40 was purchased from California Peptides (Lot No. SF104).
A1–40 stock solutions were prepared by dissolving the peptide in cold
twice distilled water to yield 2 mg/ml solutions. The peptide was pro-
cessed within 10–30 min of dissolution by diluting to 100 M with
Tris-HCl buffer (50 mM Tris, 150 mM NaCl, pH 7.4) to afford a final
peptide concentration of 100 M. The samples were incubated at 37 °C
without agitation for 1–10 days, depending on the experiment. Drugs
were dissolved in water or in 1–1.5% Me2SO solutions at 5–7 mM.
Congo Red Binding Assay for Fibril Formation—Congo Red was
prepared as described previously (25, 26) and diluted to 10 M in 50 mM
Tris-HCl, 150 mM NaCl, pH 7.4. Congo Red binding was carried out by
combining 10 l of 100 M A solutions with 90 l of 10 M Congo Red
solution mixed and incubated for 5–10 min. The binding was deter-
mined by using the UV-visible spectra (300–700 nm) collected on a
Beckman UV-visible spectrophotometer in a mini-cuvette with a 1-cm
pathlength.
Thioflavin T (ThT) Fluorescence Assay for Fibril Formation—ThT
binding assays were performed by combining 50 l of 100 M A
solutions (previously incubated at 37 °C in the absence and presence of
drugs) to 450-l solution of 10 M ThT in 10 mM phosphate, pH 7.4, and
100 mM KCl. Fluorescence measurements were recorded in a Biosys-
tems spectrofluorometer at 25 °C using a 1-cm pathlength quartz cell.
The excitation wavelength was set to 450 nm (slit width  4 nm), and
emission was monitored from 460–630 nm (slit width  8 nm). The
relative fluorescence at 482 nm was used as a measure of the amount of
fibrillar aggregates formed in solution.
Molecular Weight Determination of A1–40 Monomer and Oligomers
by Analytical Ultracentrifugation Methods—Sedimentation equilibrium
was performed at a rotor speed of 3,000–20,000 rpm using a double
sector cell with charcoal-filled epon centerpieces and sapphire windows
on 150-l samples of 100 M A in the absence and presence of drugs at
pH 7.4. All of the scans were performed at 280 nm or at 330 nm (for
solutions containing apomorphine or its derivatives) with a step size of
0.001 cm and 25 averaged scans. Samples were allowed to equilibrate
for 24–30 h, and duplicate scans of 3-h apart were overlaid to determine
that equilibrium had been reached. The data were analyzed by a non-
linear least squares analysis using the Origin software (Beckman In-
struments). The concentration profiles obtained at equilibrium were
initially fit to a single ideal species model to determine the best fitting
molecular weight as shown in Equation 1,
Ar  Exp[ln(A0) M2(1 )/2RT)(x2  x02)] E (Eq. 1)
where Ar is the absorbance at radius x, A0 is the absorbance at a
reference radius x0 (usually the meniscus), ¯ is the partial specific
volume of A (ml/g),  is the density of the solvent (g/ml),  is the
angular velocity of the rotor (radian/sec), E is the base-line error cor-
rection factor, M is the molecular weight, R is the universal gas con-
stant (8.314  107 erg/mol), and T was the temperature (Kelvin). The
partial specific volume of A1–40 (0.734 cm3/g) was estimated based on
the partial specific volumes of the component amino acid residues,
whereas the density of the buffers was calculated using polynomial
equations and tables of coefficient solution (36, 37).
Sedimentation Velocity Analytical Ultracentrifugation (SVAU)—To
probe the mechanism by which apomorphine and its derivatives inhibit
A fibril formation, sedimentation velocity was used to determine the
distribution and molecular size of A quaternary structures in the
presence and absence of drugs. A samples (100 M) in 50 mM Tris-HCl,
150 mM NaCl, pH 7.4, were incubated at 37 °C for 1–10 days in the
presence and absence of inhibitors and then transferred to 25 °C for 1–3
h before the sedimentation experiments were carried out at 20 °C. For
heterogeneous samples containing multiple species, the sedimentation
velocity absorbance profiles were analyzed to obtain the apparent dis-
tribution of sedimentation coefficients g(s*) for all of the quaternary
structures in solution using the DCDT software provided by Philo (38,
39). The molecular weight can then be estimated by combining the
Svedberg equation and Stokes equation to obtain Equation 2, which
utilizes the estimated sedimentation coefficient.
(MW)
2
3 
100s  
1
3
1 
(Eq. 2)
A Monomer Determination—SVAU was also used to determine the
amount of monomeric A and soluble aggregates in solution after sed-
imentation of A fibrils. To determine the amount of unsedimented A
in solution, two radial scans were collected at 3,000 rpm (only fibrils are
sedimentable at this speed) and 20,000–30,000 rpm (soluble high Mr
(HMW) oligomers of A sediment but not monomer). The percent of
monomeric species in solution was calculated after complete sedimen-
tation of A high Mr oligomeric species using Equation 3 at 50,000 rpm.
% Unsedimented A  1
 A260 nm, 3000 rpm  A260 nm, 20,000 –30,000 rpm)	 100 (Eq. 3)
Sedimentation equilibrium studies were also carried out on the
unsedimented species to determine whether a monomer, dimer, or a
mixture was present in solution.
Electron Microscopy—Transmission electron microscopy was used
analyze the size and structural morphology of A in the presence and
absence of drugs at 37 °C. The transmission electron microscopy sam-
ples were prepared by placing 5 l of the A solution on a carbon-coated
grid for 2 min before removing excess solution. The grid was then
washed once with distilled water before staining the sample with 1%
fresh uranyl acetate for another 2 min. The grids were thoroughly
examined to get an overall evaluation of the structures present in the
sample. All electron micrographs were taken at 100 kV using a Phillips
CM-100 electron microscope.
RESULTS
Effect of Apomorphine on Amyloid- Protein Fibrillization—
Solutions of A1–40 (100 M) were incubated at 37 °C for 1–3
days in the absence and presence of apomorphine (Fig. 1) at
FIG. 1. Chemical structure of apomorphine and one of its pos-
sible oxidation products.
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equimolar concentration. Within 2–3 days, visible (by eye) and
sedimentable aggregates (15,000  g) were observed in sam-
ples containing A1–40 alone. In contrast, A1–40 (100 M)
incubated in the presence of apomorphine (100 M) did not
show any visible aggregates. ThT fluorescence is enhanced
upon binding to amyloid fibrils, which are proportional to the
amount of fibrils in solution (40). Solutions of A only exhibited
a greatly enhanced emission at 482 nm, a characteristic for
ThT bound to amyloid fibrils (Fig. 2A). Conversely, the combi-
nation of A  apomorphine did not show an increase in ThT
fluorescence. In addition, the amyloid-specific Congo Red dye
showed no increase in the maximal absorbance or change in the
red-shifted maximum for A solutions containing apomorphine
after 3days at 37 °C (data not shown). It is noteworthy that
A1–40 solutions containing apomorphine exhibited a change
in color over time toward an intensive green color upon incu-
bation at 37 °C; the color change was significantly less than
that of apomorphine alone. This color formation is known to be
the result of a complicated multistep oxidation process with the
autoxidation of apomorphine being the initial step (41).
To further investigate the efficacy of apomorphine and its
mechanism of action, EM was used to monitor A1–40 fibril
formation in the absence and presence of apomorphine. A
alone revealed unbranched fibrils (11 nm in diameter) of
indeterminate length as the major species (Fig. 2B). The fibrils
were observed to exhibit a characteristic helical twist with
varying periodicity (Fig. 2B, inset). In contrast, co-incubation (3
days, 37 °C) of A1–40 (100 M) with apomorphine (100 M)
resulted in the accumulation of predominantly soluble nonfi-
brillar assemblies (Fig. 2C). These results suggest that apomor-
phine is acting as an effective inhibitor of A1–40 fibril forma-
tion in vitro.
Investigating the Molecular Mechanism of Apomorphine In-
hibition of A Fibril Formation by Analytical Ultracentrifuga-
tion—SVAU and EM experiments performed on solution of
A1–40 (100 M) alone (2 days, 37 °C) indicated that 85–95%
A1–40 exist as fibrils, which rapidly sediment at 3,000 rpm.
Sedimentation equilibrium studies were carried out to deter-
mine the Mr of the unsedimented material (5–15% of the total
protein as determined using Equation 3) (see “Experimental
Procedures”). The fitting of the equilibrium concentration pro-
file using a single species model yielded a Mr of 4,137  280,
FIG. 3. Sedimentation equilibrium concentration profile of
unsedimented A1–40 revealed a Mr consistent with a mono-
mer. A solution of A1–40 (100 M) alone was incubated at 37 °C (2
days), the fibrils were spun out by centrifugation (20,000 rpm), and
sedimentation equilibrium was performed on the supernatant contain-
ing unsedimented A (50,000 rpm). The equilibrium concentration pro-
file (open circle) gave an excellent fit (solid line) to a single ideal species
model as indicated by the residuals and yielded a Mr of 4,137  280.
FIG. 2. Apomorphine inhibits ThT binding and fibril forma-
tion. A, Thioflavin T in the presence of fibrillar aggregates exhibits an
emission maximum at 482 nm, characteristic of amyloid fibrils (excited
at 450 nm). Inset, emission spectra of solutions of A (100 M) alone
(solid line) and A incubated in the presence of apomorphine (100 M)
(dashed line). Solutions of A containing apomorphine did not exhibit
any fluorescence in the presence of ThT. Negatively stained electron
microscopy performed on a sample of A1–40 (100 M) in the absence
(B) or presence of apomorphine (100 M) (C) after incubation at 37 °C
for 3days. A incubated alone showed long twisted helical fibrils (B,
inset). When incubated with apomorphine, short nonfibrillar oligomeric
assemblies are the major species in solution. C, no fibrils could be
detected in A solutions containing apomorphine. Scale bar represents
100 nm.
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corresponding to the Mr of monomeric A1–40 (Fig. 3). In the
presence of apomorphine at an equimolar ratio, no sedimenta-
tion of A1–40 was observed at 3,000 rpm, consistent with the
absence of fibril formation as verified by EM. Upon increasing
the speed to 30,000 rpm, HMW-fast sedimenting species could
be detected as observed from the sedimentation profiles (Fig.
4A). An analysis of the sedimentation profiles reveals a heter-
ogeneous distribution of A-apomorphine oligomeric species
with a 30 S species being the dominant sedimenting species,
indicative of soluble HMW assemblies as the dominant species
in solution (Fig. 4B). The results obtained from SVAU experi-
ments are consistent with the EM results, which showed non-
fibrillar assemblies as the major species present in A solution
containing apomorphine.
At an apomorphine concentration of 50 M (0.5:1, apomor-
phine:A), both long unbranched fibrils and short nonfibrillar
assemblies were observed by electron microscopy (Fig. 4C).
However, the nonfibrillar assemblies remained the dominant
species in solution (70–85% of the total protein) over the
incubation period of 3 days at 37 °C. At concentrations below 50
M, apomorphine is not effective as an inhibitor, and the long
unbranched fibrils become the predominant species (Fig. 4D).
SVAU experiments carried out on the same samples used for
EM revealed the presence of two oligomeric species of A1–40
complexed to apomorphine with average sedimentation coeffi-
cients of 35 and 56 S with the 35 S species being the dominant
species (Fig. 4E). At an apomorphine concentration of 25 M
(0.25:1, apomorphine:A), 40–50% of the sample, which was
incubated at 37 °C for 3 days, sediments rapidly at 3,000 rpm,
reflecting the presence of amyloid fibrils. An analysis of the
sedimentation velocity profiles of the species remaining in so-
lution also revealed at least two populations of HMW species
with average sedimentation coefficients of 36 and 58 S (Fig.
4F). These results suggest that a 1:1 molar ratio of A to
apomorphine is required for complete inhibition of A fibril
formation in vitro (3–6 days).
The Hydroxyl Groups on Apomorphine Are Critical for Inhib-
iting A1–40 Fibril Formation—The structure of apomorphine
is characterized by the presence of two adjacent hydroxyl
groups on the D-ring of the molecule. Several structural ana-
logues of apomorphine were examined to evaluate the role of
the dihydroxy substitutions (10, 11) of the D-ring and the
N-alkyl groups in modulating the inhibitory effectiveness of
these aporphines (Fig. 4). The compounds shown in Fig. 5 were
incubated with A1–40 (100 M) under conditions that favor
fibril formation (pH 7.4, 37 °C for 3 days). The fibril formation
was evaluated by ThT fluorescence, EM, and sedimentation
velocity. Fig. 6 shows the amount of ThT binding to A in the
presence of apomorphine and its derivatives after incubation
for 3 days (37 °C). Apomorphine, D027, D029, D030, and D040
did not exhibit any increase in ThT fluorescence, whereas bul-
bocapnine, R-(-)apocodeine, isocrydine, and M121 showed ThT
binding similar in magnitude to that of A1–40 alone. SVAU
and EM studies revealed that D027, D029, D030, and D040
inhibited the formation of A1–40 fibrils in a similar manner
as apomorphine  A (data not shown). In support, these
FIG. 4. A, sedimentation velocity profiles of a sample of A (100 M) after incubation for 3 days in pH 7.4 buffer (50 mM Tris, 150 mM NaCl) in
the presence of apomorphine (100 M). Scans were acquired at 1-min intervals; for clarity, scans were acquired every 4 min as shown. The
absorbance base line at 0.6 represents absorbance of unsedimented A and excess apomorphine in solution. B, analysis of the sedimentation
profiles in A using the time-derivative (dc/dt) method. The sedimentation coefficient distribution plot g(s*) reveals the presence of heterogeneous
distribution of high Mr A-apomorphine aggregates. The solid line represents the best least square fit of the experimental data () to a two-
sedimenting species model using a Gaussian function. C and D, negatively stained electron micrograph performed on a sample of A40 (100 M)
in the presence of apomorphine at 50 M (C) and 25 M (D). At apomorphine concentrations of 	50 M, significant fibrils were formed after 3–6
days of incubation at 37 °C as seen in D. E, sedimentation coefficient distribution plot obtained by using the time-derivative analysis revealing two
populations of oligomeric species of A (formed in 50 M apomorphine) with average sedimentation coefficients of 35 and 56 S. F, similar to E but
aggregation was carried out in the presence of 25 M apomorphine, 50% of the sample sediments to the bottom of the centrifuge cell as fibrils
at 3,000 rpm. Scale bar in C and D represent 100 nm.
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samples showed the presence of numerous short oligomeric
structures with an average length of 100–400 nm and an
average diameter of 6–7 nm, suggesting that these compounds
stabilize oligomeric intermediates and block fibril formation.
SVAU studies revealed that apomorphine, D027, D029, D030,
and D040 stabilize A oligomeric species of similar size, a class
of 30–35 S species and a class of 58–65 oligomeric species. In
all cases, the compounds at 50 and 100 M were effective at
inhibiting A1–40 (100 M) fibril formation over a 3-day period
with the exception of D030, which required 100 M (1:1, A:
D030). Unlike apomorphine, bulbocapnine, R-(-)apocodeine,
isocrydine, and M121 have one or both of the hydroxyl groups
methylated. These methylated derivatives of apomorphine
showed no evidence of inhibiting A1–40 fibril formation as
discerned from the strong ThT signal, fast sedimentation, and
fibril-positive EMs. Together, these results suggest that the
hydroxyl groups on the D-ring are required for the inhibitory
effectiveness of these compounds.
Apomorphine-stabilized Nonfibrillar Assemblies Undergo a
Conversion into Amyloid Fibril after Longer Incubations—We
carried out a time-dependent study of A aggregation to deter-
mine whether the nonfibrillar assemblies formed in the pres-
ence of apomorphine, D027, D029, D030, and D040 can be
converted to amyloid fibrils. To address this possibility, the
37 °C incubation of A  drugs was extended from 3 to 9 days,
and the samples were evaluated by EM, SVAU, and ThT fluo-
rescence. Nonfibrillar assemblies remain the dominant species
during the incubation period of 1–3 days in the presence of
D030 and 1–6 days in the presence of apomorphine, D027,
D029, and D040. However, long fibrils appeared, for example,
with D030 during the 6–9-day period, which were absent in the
EM micrographs at 3 days (Fig. 7). Nevertheless, even after 9
days (37 °C), the soluble nonfibrillar assemblies remained in
the dominant species and long fibrils composed only 10–15%
total A in the sample. The slow conversion of nonfibrillar
intermediates into fibrils suggests that the short nonfibrillar
assemblies complexed to A could be an on-pathway interme-
diate of A amyloid fibril formation.
Apomorphine, D027, D029, D030, and D040 Promote A
Oligomerization but Inhibit Fibrillization—We evaluated the
rate of oligomeric intermediate(s) formation of A in the pres-
ence and absence of apomorphine, D027, D029, D030, and
D040 over the time period of 20–90 h. The incubation of
A1–40 alone for 20 h (37 °C) results in the population of
predominantly oligomeric intermediates (15–20%, see Supple-
mentary Fig. 1), which resemble previously describe protofi-
brillar A (Fig. 8) and sediment with an average sedimentation
coefficient of 20 S. Equilibrium studies revealed that the re-
maining 80–85% A (unsedimented A) in solution exist in its
monomeric form. Further incubation (40–72 h) leads to the
disappearance of monomeric as well as protofibrillar A and
the appearance of fibrils as the predominant species in the
sample (data not shown). In contrast, A (100 M) samples
incubated for 20 h at 37 °C in the presence of apomorphine and
derivatives (100 M) showed the accumulation of similar non-
fibrillar assemblies resembling protofibrils as the major species
in solution. The amount of protofibrils formed after 20-h incu-
bation of A alone was 30% of that obtained in the presence
of apomorphine, D027, D029, D030, and D040. Table I presents
a summary of the time-dependent SVAU studies of A in the
presence of inhibitors over a period of 4 days. SVAU analysis
indicates the A-inhibitor complex sediment as a broad bound-
ary of species with average sedimentation coefficients of 33, 35,
FIG. 5. Structures of apomorphine and apomorphine deriva-
tives used to evaluate the role of the dihydroxy and N-alkyl
substitutions in modulating the ability of apomorphine to in-
hibit A fibril formation.
FIG. 6. Bar graph depicting the extent of A (100 M) fibril
formation in the absence and presence of apomorphine and
apomorphine derivatives (see Fig. 5). The bar represents the extent
of fibril formation based on a quantitative Thioflavin T binding assay in
the presence of drugs at 50 M (black bars) or 100 M (white bars).
FIG. 7. Electron micrograph of negatively stained quaternary
structures deposited from a solution of A (100 M) at pH 7.4 (50
mM Tris, 150 mM NaCl) after incubation for 9 days at 37 °C in the
presence of D030, demonstrating the presence of some long
fibrils in solution. Scale bar represents 100 nm.
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33, and 31 S in the presence of D027, D029, D030, and D040,
respectively. Further incubation resulted in the population of a
second HMW oligomeric species in the presence of apomor-
phine and its derivatives (Table I). These results suggest that
apomorphine-related compounds are unique anti-amyloido-
genic agents. Interestingly, our data suggest that these com-
pounds alter the kinetics of fibrillogenesis by enhancing oli-
gomerization while inhibiting fibril formation.
Apomorphine and Its Structural Analogues Binding to A
Monomer Versus Oligomeric Intermediates—The absorbance of
apomorphine and its derivatives at 300–340 nm (A1–40 does
not show any absorbance at this wavelength) enabled us to
selectively monitor the sedimentation and estimate the molec-
ular size of soluble A inhibitor aggregates. SVAU studies
showed that after centrifugation, 5–15% A remained in the
supernatant in its monomeric form. To investigate whether
apomorphine binds to monomeric A, we carried out a sedi-
mentation equilibrium experiment on the remaining unsedi-
mented A species by monitoring at 330 nm where apomor-
phine is the sole contributor to the absorbance at this
wavelength. The equilibrium concentration distribution profile
produced an excellent fit to a single ideal species model and
yielded a Mr of 4,430  360 g/mol, corresponding to the Mr of
monomeric A (4,329 g/mol) (see Supplementary Fig. 2). Apo-
morphine is too small (334.2 g/mol) to sediment at 50,000 rpm,
and monomeric A should not be detected at 330 nm unless it
is bound to apomorphine.
We also investigated the ability of apomorphine and its anal-
ogous to act on late intermediates on the pathway of A aggre-
gation and prevent fibril formation. Apomorphine, D027, D029,
D030, and D040 (100 M) were added to preformed protofibrils.
Protofibrils were made by preincubating A at 37 °C for 18–20
h, producing a distribution of monomer (80–85%) and protofi-
brils (15–20%). The samples, A  drugs, were further incu-
bated for 3–9 days (37 °C), after which the solutions were
examined by EM and SVAU. All five compounds were shown to
interfere with amyloid fibril formation even when added after
the protofibrils had formed. For example, the co-incubation of
monomeric A with D027 resulted in the accumulation of two
populations of assemblies with average sedimentation coeffi-
cients of 31 and 65 S, respectively (Fig. 9A). In comparison,
D027 added to preformed protofibrils resulted in the accumu-
lation of a wider distribution of quaternary structures (at
least three populations of nonfibrillar species with average
sedimentation values of 32, 48, and 78 S) and no fibril for-
mation (Fig. 9B-C). Apomorphine, D029, and D040 exhibited
a similar behavior with a slightly different size of assemblies
being populated. In all cases, fibril formation (i.e. protofibrils
assembling into amyloid fibrils) was inhibited. D030 was
shown to be the least effective compound for inhibiting pro-
tofibril assembly into fibrils as observed using EM. These
similar binding affinities and our EM studies suggest that
protofibrils and the nonfibrillar assemblies formed in the
presence of apomorphine and its analogues are similar if not
identical.
Apomorphine Autoxidation Is Required for Inhibiting Aggre-
gation—The rapid autoxidation of apomorphine, which occurs
within the first 1–3 h of incubation at 37 °C (50 mM Tris-HCl 
150 mM NaCl, pH 7.4) (33), suggests that one of the oxidation
intermediates or products may be responsible for inhibiting
fibril formation. To test this hypothesis, we carried out an A
fibril formation assay using a one-month-old (4 °C) inhibitor
stock solution (oxidized, colored solution) or a freshly prepared
stock solution (clear solution) with or without the reducing
agent sodium metabisulfite (1% (v/v), clear solution) (42). The
samples were incubated at 37 °C, pH 7.4, for 3 days before
being evaluated by ThT and EM. An evaluation by ThT reveals
similar inhibition of fibril formation for both the oxidized com-
pounds and the freshly dissolved compounds, which rapidly
oxidizes, consistent with the idea that the inhibitory effect is
associated with an autoxidation product(s) (Fig. 10). An ad-
dition of sodium metabisulfite to A solution samples con-
taining apomorphine, D027, D029, D030, and D040 resulted
in the restoration of the ThT signal (similar to A alone),
indicating the presence of fibrils. Further support is provided
by the EM examination of A samples incubated with either
aged or freshly prepared stock solutions of apomorphine or
D027, revealing an effective inhibition of A fibril formation
in both cases over a 3-day period (37 °C) (Fig. 11). Conversely,
an examination of the samples containing sodium metabisul-
fite revealed long unbranched fibrils similar to those ob-
served for A alone as the major species (data not shown).
These results suggest that autoxidation is required for the
anti-fibrillization activity observed for these compounds.
DISCUSSION
The accumulation of A deposits in the form of amyloid
plaques in the brain parenchyma is thought to play a critical
role in the pathogenesis of AD. Recent studies from several
laboratories suggest that the process of A aggregation in vivo
is responsible for triggering a cascade of physiological events
that are critical for the initiation and progression of AD. There-
fore, inhibiting the aggregation or deposition of A is thought
to be a promising therapeutic strategy to combat AD.
The recent application of analytical ultracentrifugation (sed-
imentation velocity and sedimentation equilibrium) in parallel
with imaging methods (EM and atomic force microscopy) to
probe the mechanism of fibril formation has allowed for the
FIG. 8. Electron micrograph of negatively stained quaternary
structures deposited from a solution of A (100 M) at pH 7.4 (50
mM Tris, 150 mM NaCl) after incubation for 18 h at 37 °C, dem-
onstrating the presence of protofibrils as the predominant form
of A quaternary structures. Scale bar represents 100 nm.
TABLE I
Summary of the time-dependent SVAU studies of A in the presence
of inhibitors over a period of 4 days
A1–40 (100 M) was incubated (37 °C) alone or in the presence of
apomorphine derivatives (100 M), and 400 l of the samples were
taken at 20, 50, and 90 h for analysis by sedimentation velocity ana-
lytical ultracentrifugation. The S values represent the predominant
populations of oligomeric A1–40 species as determined by fitting the
experimental data (the sedimentation coefficient distribution plots
g(s*)) to a one-, two-, or three-species model using a Gaussian function.
Sample 20 h 50 h 90 h
A1–40 20 S Fibrils Fibrils
A1–40  D027 33 S 31 S, 65 S 30 S, 50 S, 76 S
A1–40  D029 35 S 36 S, 70 S 26 S, 51 S, 70 S
A1–40  D030 23 S, 103 S
A1–40  D040 31 S 36 S, 61 S 36 S, 67 S
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observation and characterization of soluble HMW oligomeric
intermediates formed during fibrillogenesis for several amyloi-
dogenic proteins including A (34, 43–47). In this paper, ana-
lytical ultracentrifugation and EM were employed to probe the
mechanism by which catecholamines such as apomorphine and
its derivatives interact with A and inhibit fibril formation in
vitro. Our SVAU studies clearly demonstrate that apomorphine
and its structural analogues bind to early oligomeric interme-
diates of A, resulting in a significant delay in fibril formation
and the accumulation of protofibrillar intermediates. The pro-
tofibrillar intermediates stabilized by apomorphine, D027,
D029, D030, and D040 exhibit molecular mass distribution and
structural morphologies that resemble to some extent those
observed in the case of A alone as determined by SVAU and
EM studies.
Although current evidence implicates the process of A ag-
gregation in the pathogenesis of AD, it remains to be resolved
whether a misfolding intermediate, protofibrils, amyloid
fibrils, or some combination of species are the toxic assemblies
associated with the pathogenesis of AD. Understanding the
relative importance of protofibrillar intermediates and fibrils
in the pathogenesis of AD is critical for elucidation of the
molecular etiology of AD. Studies by several groups suggest a
potential pathological role for preamyloid oligomeric interme-
diates in the pathogenesis of AD (17, 35, 46, 48, 49). Therefore,
the development of a small molecule-based strategy for manip-
ulating the amyloid fibril formation pathway, such that each of
these species can be populated exclusively, is critical for the
elucidation of their relative toxicity and the development of
drugs that block their formation as a potential therapeutic
strategy for treating AD. If amyloid fibrils are the toxic species,
small molecules that inhibit amyloid fibril formation could
yield a potential therapy for delaying and/or preventing amy-
loid-associated neurotoxicity. A delay in amyloid fibril forma-
tion may allow for a more efficient clearance of toxic preamy-
loid intermediates as well as preformed amyloid fibrils,
producing an affective therapy. On the other hand, if protofi-
brillar species such as those stabilized by apomorphine and its
derivatives are the toxic agents in AD, in vivo conditions or
small molecules that promote their formation and accumula-
tion should produce a more severe AD phenotype and acceler-
ate disease progression. Catecholamines including apomor-
phine, dopamine, norepinephrine, and epinephrine have been
shown to enhance A toxicity in cultured hippocampal neurons,
most probably because of the formation of reactive oxygen
species, semiquinones quinones, and melanin-like pigments,
FIG. 9. A, sedimentation coefficient distribution of a sample of A
(100 M) at pH 7.4 (50 mM Tris, 150 mM NaCl) after incubation for 3
days at 37 °C in the presence of D027 (100 M) obtained from a two-
sedimenting species fit (solid line) of the experimental data (). B,
sedimentation velocity profiles of a solution of A (100 M), which was
preincubated at 37 °C for 18 h, after which D027 was added and the
sample was further incubated for 9 days at 37 °C. The sedimentation
profiles reveal at least three sedimenting boundaries (see arrows a, b,
c). C, sedimentation velocity analysis of the profiles shown in B ob-
tained by fitting the data to three-sedimenting species model.
FIG. 10. Bar graph depicting the extent of A fibril formation
in the absence and presence of apomorphine, D027, D029, and
D030 using freshly prepared stock solutions (dark bars), aged
stock solutions (gray bars), and stock solution of the compounds
containing 1% (v/v) sodium metabisulfite. The bar represents the
extent of fibril formation based on a quantitative Thioflavin T emission
(emission  482 nm; excitation  450 nm).
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all of which are associated with the autoxidation of these com-
pounds and are thought to mediate their cytotoxicity (50, 51).
In addition, A-peptides have been shown to enhance the oxi-
dation of hydroxylamine derivatives without the formation of
peptide-derived free radicals (52). The results presented in this
paper suggest that autoxidation products of apomorphine and
its derivatives could exacerbate A toxicity by stabilizing toxic
A protofibrillar intermediates. Recent evidence has begun to
suggest that soluble intermediates are neurotoxic; therefore,
reagents such as apomorphine may become a valuable tool to
test this hypothesis in vivo.
Apomorphine is known to undergo rapid autoxidation in
aqueous solutions, suggesting that an oxidation product is
probably responsible for the observed anti-amyloidogenic prop-
erties of apomorphine. In support, we have found that blocking
the autoxidation of these molecules either through modification
of the hydroxyl groups or by using stabilizing agents such as
sodium metabisulfite results in the loss of the inhibitory effect
of these molecules. Compounds such as D030, which possess an
additional hydroxyl group on the adjacent ring exhibited, re-
duced inhibitory activity most probably because of their in-
creased susceptibility to additional oxidation processes and
suggest that a specific autoxidation product is an effective
inhibitor of A fibril formation. An interesting property of
apomorphine and its active derivatives is that they seem to
target protofibrillar intermediates on the fibril formation path-
way of A. Although protofibrillar intermediates were observed
in all A incubations, they were present longer in incubations
containing apomorphine and its derivatives containing unmod-
ified hydroxyl groups. Indeed, Lansbury and coworkers (53)
have recently reported that catechol-containing compounds in-
cluding dopamine (L-DOPA), norepinephrine, and apomorphine
inhibit 
-synuclein fibrillization and result in the kinetic sta-
bilization of protofibrillar intermediates (53). Similar to our
observations with A, the inhibitory activity of these com-
pounds was abolished by the addition of antioxidant (sodium
metabisulfite), suggesting that oxidation is critical for inhibit-
ing fibril formation. To investigate whether the catechol moiety
is sufficient for inhibiting A fibril formation, the activity of the
naturally occurring catecholamines, dopamine and norepi-
nephrine, was compared with apomorphine and its derivatives.
Apomorphine and its derivatives were shown to be more effec-
tive inhibitors of A (100 M) fibril formation at 50 M (80–
92% inhibition) than dopamine (49%) and norepinephrine
(32%) (Fig. 12). The addition of apomorphine and its deriva-
tives at higher concentrations (100–200 M) resulted in 
95%
inhibition of fibril formation, whereas dopamine and norepi-
nephrine resulted in 82 and 65% inhibition of fibril forma-
tion, respectively. These results demonstrate that the catechol
moiety contributes significantly to the anti-amyloid activity of
these compounds, but it is not the only factor. Apomorphine has
an additional ring structure that distinguishes it from natu-
rally occurring catechols making it more hydrophobic, which
could increase its affinity for binding especially with A, which
has a hydrophobic core. In addition, the nature and reactivity
of the intermediate oxidation products have been demonstrated
to vary considerably among catechols, suggesting that the ac-
tive autoxidation species could be different for each class of
catechols. Dopamine-derived orthoquinone was shown to mod-
ify a small portion of the 
-synuclein monomer and inhibit

-synuclein aggregation. Although apomorphine has been ob-
served to modify proteins such as albumin (54), we have not
been able to detect any covalent modification of A by these
compounds using high pressure liquid chromatography and
liquid chromatography-tandem mass spectrometry methods.2
However, an analysis of the A solutions incubated in the
presence of apomorphine by liquid chromatography-tandem
mass spectrometry suggests that the process of apomorphine
oxidation results in the oxidation of the methionine in A.
Recent findings by several laboratories demonstrate that ox-
idation of the amyloidogenic proteins A40 (55), A42 (56),
and 
-synuclein (57) attenuates their oligomerization prop-
erties and inhibits fibrillization. Taken together, these re-
2 H. A. Lashuel, D. M. Hartley, D. Balakhaneh, A. Aggarwal,
S. Teichberg, and D. Callaway, unpublished results.
FIG. 12. A comparison of the inhibition of amyloid fibril for-
mation of naturally occurring catecholamines, dopamine and
norepinephrine, versus apomorphine and its derivatives. The
bar represents the extent of fibril formation based on a quantitative
Thioflavin T binding assay in the presence of each of the drugs listed at
50 M (black bars), 100 M (gray bars), and 200 M (white bars).
FIG. 11. Electron micrographs of
negatively stained quaternary struc-
tures deposited from solutions of A
(100 M) at pH 7.4 (50 mM Tris, 150 mM
NaCl) in the presence of apomor-
phine from aged stock solution (A)
and freshly prepared stock solution
(B) and in the presence of D027 from
aged stock solution (C) and freshly
prepared D027 stock solution (D).
Panels E and F show electron micro-
graphs from solutions of A incubated
with apomorphine and D027, respec-
tively, for 4 days at 37 °C. Scale bar rep-
resents 100 nm.
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sults suggest that catecholamine-mediated oxidation of me-
thionine and catecholamines binding to A monomer and
protofibrils could have a synergistic effect in inhibiting amy-
loid fibril formation. It is possible that apomorphine and it’s
derivatives may have the same effect on stabilizing protofi-
brils generated from other amyloidogenic proteins and may
be a very useful tool for understanding the role of protofibrils
in other amyloid diseases.
In addition to its apparent anti-amyloidogenic properties,
apomorphine is known to act as a potent antioxidant and
protect lipids and proteins from radical damage (58). Also,
neurotrophic properties have also been reported for apomor-
phine and its derivatives, giving these compounds multiple
biological activities (59). Radical scavengers seem to have a
high potential for attenuating neurodegenerative diseases.
Apomorphine as a drug is known to quickly pass through the
nasal and intestinal mucosa and cross the blood brain barrier
and has been approved by the FDA for treating patients with
Parkinson’s disease, primarily to manage the on-off fluctuation
associated with L-DOPA treatment (60). Apomorphine could be
an important candidate as a potential neuroprotective agent in
the treatment of AD, assuming amyloid fibril formation and
oxidative stress are causative (19). Conversely, if apomorphine
does stabilize protofibrils, treatment may potentially exacer-
bate neurodegenerative diseases that produce neurotoxic pro-
tofibrils. Therefore, apomorphine may be a valuable tool in
animal models to test the hypothesis that protofibrils, at least
in part, mediate neurotoxicity. Together, our studies are con-
sistent with previous studies, which demonstrate that the ag-
gregation pathway of A can be manipulated by small mole-
cules or peptidomimetics that stabilize intermediates on the
aggregation pathway, ultimately slowing down or preventing
amyloid fibrils from being formed (16, 61–65). The ability to
use small molecules, such as the those presented in this paper,
to selectively interfere and/or block the aggregation of A at
different stages on the amyloid fibril formation pathway is
critical for investigating the relationship between preamyloid
intermediates and fibrils in the pathogenesis of AD. Addi-
tional studies are currently underway to identify the regions
in A with which these compounds interact. Studies on dif-
ferent derivatives of apomorphine are needed to identify
more stable and potent inhibitors of A aggregation and to
establish the exact mechanism by which these compounds
interfere with A fibril formation. It is probable that these
compounds function either through modulating the kinetics
of conformational changes required for fibril growth or by
decreasing the rate of monomer addition to preamyloid
assemblies. Together, our results suggest that the use of
apomorphine-like molecules will contribute to a better under-
standing of the underlying mechanism(s) of A fibrillogenesis
in animal models and neurodegeneration. Moreover, these
reagents may provide the basis for the development of new
aggregation inhibitors as a therapeutic strategy for delaying
or treating AD.
Note Added in Proof—After submission of this paper, we observed
that the relative efficacy of the inhibitors reported varied depending on
the lot and source of the peptide when the stocks were prepared in
water. However, dissolving the peptide in Me2SO  H2O  Tris pre-
vented this lot to lot variation. Peptides were dissolved in neat Me2SO
at a concentration of 5% (A1–40/vol Me2SO) and then in water and in
Tris, pH 7.4. Final concentrations of peptide, Me2SO, and Tris were 100
M, 2%, and 10 mM, pH 7.4, respectively.
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